Jason Callahan
Jason Callahan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Rodney John Hicks
University of Melbourne 6 Department of Medicine, St Vincent’s Hospital Fitzroy, Australia
9 shared publications - Andjelija Zivanovic Bujak
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
7 shared publications - Chee Khoon Lee
NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
7 shared publications - Chen-Fang Weng
Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
7 shared publications - Courtney T. van Geelen
Peter MacCallum Cancer Centre 9 Melbourne
7 shared publications - Elizabeth F. Blackley
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
7 shared publications
Latest Publications
- Open Access
- 17 September 2024
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 55 (1) , 11-20
Total-Body PET/CT: Pros and Cons
- 17 September 2024
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 55 (1) , 11-20
Open AccessTotal-Body PET/CT: Pros and Cons
- 28 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 27, 237-244
Preliminary Study of Pseudo-PET Image Synthesis of Glucose Metabolism from Early-Phase PET Images of an Uncorrelated Radiotracer
Positron Emission Tomography (PET) is widely used in modern medicine to identify diseases such as cancer, neurological disorders, and heart conditions to observe biochemical functional processes. Despite its widespread usage, the requirement for different radiotracers to observe separate biological processes imposes resource constraints and patient inconvenience. Recent clinical studies suggest the utility of using a single radiotracer to examine more than one distinct biological process.In this paper, we present a preliminary study of a novel framework for generating pseudo-equilibrium PET images of glucose metabolism from early-phase images of an uncorrelated radiotracer (i.e., a radiotracer targeting a different biological process). The proposed framework further includes a quantitative analysis of the synthesized images for noise and structural similarity, as well as a radiomics analysis. The proposed framework achieved an R-squared score of 0.961 and SSIM of 0.913 when synthesized images were evaluated with the target images. The results show a significant improvement over the baseline of averaged input (R-squared = 0.689, SSIM = 0.801), which was also confirmed by the radiomics analysis.
- 28 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 27, 237-244
Preliminary Study of Pseudo-PET Image Synthesis of Glucose Metabolism from Early-Phase PET Images of an Uncorrelated Radiotracer
Positron Emission Tomography (PET) is widely used in modern medicine to identify diseases such as cancer, neurological disorders, and heart conditions to observe biochemical functional processes. Despite its widespread usage, the requirement for different radiotracers to observe separate biological processes imposes resource constraints and patient inconvenience. Recent clinical studies suggest the utility of using a single radiotracer to examine more than one distinct biological process.In this paper, we present a preliminary study of a novel framework for generating pseudo-equilibrium PET images of glucose metabolism from early-phase images of an uncorrelated radiotracer (i.e., a radiotracer targeting a different biological process). The proposed framework further includes a quantitative analysis of the synthesized images for noise and structural similarity, as well as a radiomics analysis. The proposed framework achieved an R-squared score of 0.961 and SSIM of 0.913 when synthesized images were evaluated with the target images. The results show a significant improvement over the baseline of averaged input (R-squared = 0.689, SSIM = 0.801), which was also confirmed by the radiomics analysis.
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S578
EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S578
EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003).Significance:Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting.This article is highlighted in the In This Issue feature, p. 2007
- Open Access
- 30 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (9) , 2058-2073
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003). Significance: Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting. This article is highlighted in the In This Issue feature, p. 2007
- 30 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (9) , 2058-2073
Open AccessAlpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2− and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083–0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078–0.60, P = 0.003). Significance: Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting. This article is highlighted in the In This Issue feature, p. 2007